Cargando…

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452300/
https://www.ncbi.nlm.nih.gov/pubmed/34414680
http://dx.doi.org/10.1002/psp4.12698